​

Bionomics (BNOX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

BNOX Stock Forecast

Bionomics stock forecast is as follows: an average price target of $6.00 (represents a 2428.45% upside from BNOX’s last price of $0.24) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

BNOX Price Target

The average price target for Bionomics (BNOX) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 2428.45% upside from BNOX's last price of $0.24.

BNOX Analyst Ratings

Buy

According to 3 Wall Street analysts, Bionomics's rating consensus is 'Buy'. The analyst rating breakdown for BNOX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Bionomics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 19, 2022Joshua SchimmerEvercore ISI$6.00$5.891.87%2428.45%

The latest Bionomics stock forecast, released on Dec 19, 2022 by Joshua Schimmer from Evercore ISI, set a price target of $6.00, which represents a 1.87% increase from the stock price at the time of the forecast ($5.89), and a 2428.45% increase from BNOX last price ($0.24).

Bionomics Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.24$0.24$0.24
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Bionomics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bionomics's last price of $0.24. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jun 13, 2024H.C. WainwrightBuyBuyHold
Mar 10, 2023Evercore ISIOutperformUpgrade
Dec 19, 2022William BlairOutperformOutperformHold

Bionomics's last stock rating was published by H.C. Wainwright on Jun 13, 2024. The company gave BNOX a "Buy" rating, the same as its previous rate.

Bionomics Financial Forecast

Bionomics Revenue Forecast

Sep 24Jun 24Jun 23Mar 23Dec 22
Revenue----$65.91K
Avg Forecast-$2.64M$-524.11K$2.56M$5.07M
High Forecast-$2.64M$-524.11K$2.56M$5.07M
Low Forecast-$2.64M$-524.11K$2.56M$5.07M
# Analysts-1-11
Surprise %----0.01%

Bionomics's average Quarter revenue forecast for Mar 23 based on 1 analysts is $2.56M, with a low forecast of $2.56M, and a high forecast of $2.56M. BNOX's average Quarter revenue forecast represents a 3784.16% increase compared to the company's last Quarter revenue of $65.91K (Dec 22).

Bionomics EBITDA Forecast

Sep 24Jun 24Jun 23Mar 23Dec 22
# Analysts-1-11
EBITDA----$-5.48M
Avg Forecast-$-528.72K$104.82K$-512.00K$-1.01M
High Forecast-$-528.68K$104.82K$-512.00K$-1.01M
Low Forecast-$-528.75K$104.82K$-512.00K$-1.01M
Surprise %----5.41%

undefined analysts predict BNOX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Bionomics's previous annual EBITDA (undefined) of $NaN.

Bionomics Net Income Forecast

Sep 24Jun 24Jun 23Mar 23Dec 22
# Analysts-1-11
Net Income----$-5.44M
Avg Forecast$35.42M$-22.15M$-30.04M$-16.95M$44.67M
High Forecast$35.42M$-22.15M$-30.04M$-16.95M$44.67M
Low Forecast$35.42M$-22.15M$-30.04M$-16.95M$44.67M
Surprise %-----0.12%

Bionomics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BNOX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Bionomics SG&A Forecast

Sep 24Jun 24Jun 23Mar 23Dec 22
# Analysts-1-11
SG&A----$2.85M
Avg Forecast-$302.14M$-59.90M$292.59M$579.01M
High Forecast-$302.16M$-59.90M$292.59M$579.01M
Low Forecast-$302.12M$-59.90M$292.59M$579.01M
Surprise %----0.00%

Bionomics's average Quarter SG&A projection for Mar 23 is $292.59M, based on 1 Wall Street analysts, with a range of $292.59M to $292.59M. The forecast indicates a 10168.17% rise compared to BNOX last annual SG&A of $2.85M (Dec 22).

Bionomics EPS Forecast

Sep 24Jun 24Jun 23Mar 23Dec 22
# Analysts-1-11
EPS----$-0.72
Avg Forecast$2.27$-1.42$-1.93$-1.09$2.86
High Forecast$2.27$-1.42$-1.93$-1.09$2.86
Low Forecast$2.27$-1.42$-1.93$-1.09$2.86
Surprise %-----0.25%

According to undefined Wall Street analysts, Bionomics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BNOX previous annual EPS of $NaN (undefined).

Bionomics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BNOXBionomics$0.27$6.002122.22%Buy
AVTEAerovate Therapeutics$2.56$13.00407.81%Hold
ANEBAnebulo Pharmaceuticals$1.31$6.00358.02%Buy
PMVPPMV Pharmaceuticals$1.52$6.00294.74%Buy
ANTXAN2 Therapeutics$1.34$5.00273.13%Buy
ACRVAcrivon Therapeutics$7.21$22.50212.07%Buy
ADAGAdagene$2.10$5.00138.10%Buy
RZLTRezolute$4.44$6.6750.23%Buy

BNOX Forecast FAQ

Is Bionomics a good buy?

Yes, according to 3 Wall Street analysts, Bionomics (BNOX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of BNOX's total ratings.

What is BNOX's price target?

Bionomics (BNOX) average price target is $6 with a range of $6 to $6, implying a 2428.45% from its last price of $0.237. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Bionomics stock go up soon?

According to Wall Street analysts' prediction for BNOX stock, the company can go up by 2428.45% (from the last price of $0.237 to the average price target of $6), up by 2428.45% based on the highest stock price target, and up by 2428.45% based on the lowest stock price target.

Can Bionomics stock reach $0?

BNOX's average twelve months analyst stock price target of $6 supports the claim that Bionomics can reach $0 in the near future.

What are Bionomics's analysts' financial forecasts?

Bionomics's analysts financial forecasts for the fiscal year (Jun 2023) are as follows: average revenue is $7.1M (high $7.1M, low $7.1M), average EBITDA is $-1.42M (high $-1.42M, low $-1.42M), average net income is $-2.319M (high $-2.319M, low $-2.319M), average SG&A $811.7M (high $811.7M, low $811.7M), and average EPS is $-0.149 (high $-0.149, low $-0.149). BNOX's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $2.64M (high $2.64M, low $2.64M), average EBITDA is $-529K (high $-529K, low $-529K), average net income is $-22.148M (high $-22.148M, low $-22.148M), average SG&A $302.14M (high $302.16M, low $302.12M), and average EPS is $-1.42 (high $-1.42, low $-1.42).

Did the BNOX's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Dec 2022), Bionomics's revenue was $65.91K, missing the average analysts' forecast of $5.07M by -98.70%. The company's EBITDA was $-5.481M, beating the average prediction of $-1.013M by 440.96%. Bionomics's net income was $-5.44M, missing the average estimation of $44.67M by -112.18%. The company's SG&A was $2.85M, missing the average forecast of $579.01M by -99.51%. Lastly, the company's EPS was $-0.72, missing the average prediction of $2.86 by -125.14%